BioRestorative Therapies, Inc. (BRTX): Cost of Revenue

Annual figures by period end, from SEC filings.

$23.8K

Year ended 2025-12-31

$28.3K

Trailing 12 months to 2026-03-31

2024-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$23.8K	-15.1%	2026-03-26, From 2025-01-01
2024-12-31	$28.1K	n/a	2026-03-26, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Services-Misc Health & Allied Services, NEC), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
BioRestorative Therapies, Inc. (BRTX)	2025-12-31	$23.8K	-15.1%
Mangoceuticals, Inc. (MGRX)	2025-12-31	$54.4K	-41.7%
Charming Medical Ltd (MCTA)	2026-03-31	$35.2K	+127.0%
Cryo Cell International Inc (CCEL)	2025-11-30	$7.38M	-7.2%
Viemed Healthcare, Inc. (VMD)	2025-12-31	$114.82M	+26.1%
Sotera Health Co (SHC)	2025-12-31	$518.08M	+4.0%
Progyny, Inc. (PGNY)	2025-12-31	$984.18M	+7.7%

Compare BRTX, MGRX, MCTA, CCEL side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗